The US Food and Drug Administration (FDA) has cleared pharmaceutical company Glenmark’s investigational new drug (IND) application to begin a phase I trial of GBR 1302-BEAT to treat HER2+ cancers.

Bi-specific engagement by antibodies based on the T-cell receptor (BEAT) has been designed to produce bi-specific antibodies (bsAbs) that engage with two targets to affect cancer cells, which in the case of HER2+ cancers redirects cytolitic T-cells.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Glenmark president and chief medical officer Fred Grossman said: “We believe GBR 1302 may have utility across a broad range of HER2+ tumour types.

“Data from preclinical studies are very encouraging.

"We believe GBR 1302 may have utility across a broad range of HER2+ tumour types."

“Based on its novel mechanism of redirecting T-cells to HER2+ cancer cells, GBR 1302 has the potential to become an important therapy for previously treated and, eventually, newly diagnosed HER2+ tumours.”

See Also:

The phase I trial will be carried out in two parts, the dose escalation and expansion.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The dose-escalation will examine patients with previously treated HER2+ tumours in order to test safety and tolerability, as well as the pharmacokinetics and preliminary anti-tumour activity of the maximum dose of GBR 1302-BEAT .

The expansion will examine the same population treated with the maximum tolerated dose to determine early proof-of-concept.

Preclinical studies suggested that GBR 1302 is supposedly active against a range of HER2-expressing tumour types, including breast, gastric and other cancers.